BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, July 3, 2025
Home » non-small-cell lung cancer

Articles Tagged with ''non-small-cell lung cancer''

3D illustration of cancer in crosshairs

Dato data lack means upside for Gilead; Padcev 'must-win' does win

Sep. 22, 2023
By Randy Osborne
Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form the basis of global approval bids, as Astrazeneca plc with Daiichi Sankyo Co. Ltd. unveiled interim results from a study called Tropion-Breast01. Targeting trophoblast cell surface antigen 2, datopotamab deruxtecan (dato) hit the mark in progression-free survival for patients with hormone receptor-positive, HER2-low or negative breast cancer in the study called Tropion-Breast01.
Read More
Lung cancer illustration

Daiichi Sankyo’s HER3 ADC shows promise in EGFR-mutated advanced NSCLC

Sep. 11, 2023
By Tamra Sami
Daiichi Sankyo Co Ltd.’s HER3-directed antibody-drug conjugate patritumab deruxtecan showed clinically meaningful and durable responses in patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC) in the Herthena-Lung1 phase II trial.
Read More
Cancer

YK-029A shows preclinical efficacy in several EGFR mutant lung cancer models

Sep. 7, 2023
Current standard of care treatment for non-small-cell lung cancer (NSCLC) tumors harboring mutations of the epidermal growth factor receptor (EGFR) gene includes a wide variety of tyrosine kinase inhibitors (TKIs). There are, however, some types of NSCLC tumors, such as the ones with EGFR exon 20 insertion mutations, that have a much-limited margin of therapeutic intervention. Researchers from Suzhou Puhe Pharmaceutical Technology Co. Ltd. have reported the identification and early evaluation of a small-molecule third-generation TKI of EGFR, YK-029A, being developed as an anticancer agent.
Read More

Alecensa sends a positive phase III message to Genentech in early NSCLC

Sep. 1, 2023
By Randy Osborne
Roche Holding AG’s Genentech subsidiary has broken new ground with a victory in phase III testing of the oral, anaplastic lymphoma kinase (ALK) inhibitor Alecensa (alectinib) in early stage, ALK-positive non-small-cell lung cancer (NSCLC). The drug, well known to doctors in the advanced setting, was compared with platinum-based chemotherapy and met its primary endpoint of disease-free survival at a prespecified interim analysis.
Read More
The epidermal growth factor receptor in the inactive (left) and active (right) form.
Cancer

First cell-active covalent EGFR inhibitor described

Aug. 31, 2023
Epidermal growth factor receptor (EGFR) is involved in cell proliferation leading to malignant transformation, and for that it is considered a therapeutic target for treatment and prevention in lung and other cancers.
Read More
Cancer cell, dropper, test tubes
Immuno-oncology

Tscan’s PRAME-targeting TCR T-cell product cleared to enter clinic

Aug. 29, 2023
Tscan Therapeutics Inc. has received FDA clearance of its IND application for TSC-203-A0201, a T-cell receptor (TCR)-engineered T-cell therapy (TCR-T) targeting preferentially expressed antigen in melanoma (PRAME). PRAME is expressed in melanoma and other solid tumors, including head and neck cancers and non-small-cell lung cancers. TSC-203-A0201 is specific for patients with HLA type A*02:01.
Read More
Cancer

Medshine Discovery describes new coumarin compounds for cancer

Aug. 28, 2023
Medshine Discovery Inc. has identified coumarin compounds reported to be useful for the treatment of cancer.
Read More
Cancer cells being destroyed by immunotherapy

Lucky leak? TIGIT targeters rise on accidental disclosure by Roche

Aug. 23, 2023
By Jennifer Boggs
The narrative of TIGIT-targeting immunotherapy development, beset by negative news in recent months, has found a positive plotline again, thanks to what Roche Holding AG referred to as “an inadvertent disclosure” of a second interim analysis from the phase III Skyscraper-01 study testing anti-TIGIT candidate tiragolumab with anti-PD-L1 antibody Tecentriq (atezolizumab) in non-small-cell lung cancer.
Read More
Cancer

Preclinical characterization of novel TS inhibitor DG-1 presented

Aug. 23, 2023
Thymidylate synthase (TS) is an enzyme essential for DNA synthesis and cell proliferation and is a potential oncoprotein itself. Consequently, TS is considered a molecular target for malignant tumors.
Read More
Antibodies attacking cancer cell
Immuno-oncology

Novarock's bispecific antibody NBL-028 cleared to enter clinic for CLDN6-expressing tumors

Aug. 18, 2023
Novarock Biotherapeutics Ltd., a subsidiary of CSPC Pharmaceutical Group Ltd., has received FDA approval of its IND application for NBL-028, a CLDN6-CD137 bispecific antibody.
Read More
Previous 1 2 … 17 18 19 20 21 22 23 24 25 … 41 42 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 2, 2025.
  • Medtronic Vitalflow ECMO

    Medtronic receives CE mark for its Vitalflow ECMO system

    BioWorld MedTech
    Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...
  • Drug vials

    Industry could feel fallout of Pfizer vaccine scrutiny

    BioWorld
    In subpoenaing a former Pfizer Inc. official to appear before the U.S. House Judiciary Committee July 22, Judiciary Chair Jim Jordan, R-Ohio, signaled legislative...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing